Trials / Completed
CompletedNCT00115635
Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer
A Phase I/II Study With Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Herlev Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to determine the optimal dose of the combination of docetaxel and gemcitabine in patients with hormone refractory prostate cancer, and evaluate this dose with respect to efficacy and toxicity in a phase II trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | docetaxel | |
| DRUG | gemcitabine |
Timeline
- Start date
- 2005-03-01
- Completion
- 2007-07-01
- First posted
- 2005-06-24
- Last updated
- 2007-10-02
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00115635. Inclusion in this directory is not an endorsement.